Tysabri back on market.
Sheridan
Cormac
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D064420:Drug-Related Side Effects and Adverse Reactions; D005062:European Union; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000517:prevention & control; D040541:Marketing / Q000191:economics / Q000639:trends*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab